ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)

Clinical trials for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) explained in plain language.

Never miss a new study

Get alerted when new ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) trials appear

Sign up with your email to follow new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Not yet finished but already full! 1

New pill aims to stop aggressive Lymphoma's return

Disease control Not yet recruiting

This study is testing if a daily pill called golidocitinib can help keep an aggressive type of blood cancer (peripheral T-cell lymphoma) from coming back after initial chemotherapy. It will involve about 136 adults whose cancer has shrunk or disappeared after first treatment but …

Matched conditions: ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)

Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control

Last updated Mar 16, 2026 15:25 UTC

ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)

Get alerted when new ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) trials appear

New pill aims to stop aggressive Lymphoma's return